Moderna (NASDAQ:MRNA) Hits New 12-Month Low – What’s Next?

Shares of Moderna, Inc. (NASDAQ:MRNA) hit a new 52-week low during trading on Thursday . The stock traded as low as $55.42 and last traded at $55.57, with a volume of 2234411 shares traded. The stock had previously closed at $57.46.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MRNA. Evercore ISI reissued an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a report on Thursday, June 27th. Leerink Partners lowered their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Piper Sandler reduced their price objective on Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. Finally, William Blair reissued a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus target price of $97.18.

Moderna Price Performance

The business has a fifty day moving average price of $70.75 and a 200 day moving average price of $104.56. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The company has a market capitalization of $20.73 billion, a price-to-earnings ratio of -3.45 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. During the same quarter last year, the company earned ($3.62) EPS. On average, research analysts expect that Moderna, Inc. will post -9.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $117.80, for a total transaction of $1,767,000.00. Following the completion of the transaction, the director now owns 2,239,015 shares of the company’s stock, valued at $263,755,967. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $117.80, for a total transaction of $1,767,000.00. Following the completion of the transaction, the director now owns 2,239,015 shares in the company, valued at approximately $263,755,967. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,184 shares of company stock valued at $3,804,931. 15.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently modified their holdings of the stock. Profund Advisors LLC raised its position in shares of Moderna by 20.9% during the second quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after purchasing an additional 9,719 shares during the period. Vontobel Holding Ltd. increased its stake in Moderna by 148.2% in the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock worth $7,758,000 after purchasing an additional 69,313 shares in the last quarter. Tobam raised its holdings in Moderna by 121.6% during the 3rd quarter. Tobam now owns 27,794 shares of the company’s stock worth $1,857,000 after buying an additional 15,249 shares during the period. Marshall Wace LLP lifted its stake in Moderna by 295.5% during the second quarter. Marshall Wace LLP now owns 35,200 shares of the company’s stock valued at $4,180,000 after buying an additional 26,300 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Moderna in the second quarter worth approximately $4,036,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.